These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 18275907)

  • 1. Strategies and tactics for optimizing the Hit-to-Lead process and beyond--a computational chemistry perspective.
    Manly CJ; Chandrasekhar J; Ochterski JW; Hammer JD; Warfield BB
    Drug Discov Today; 2008 Feb; 13(3-4):99-109. PubMed ID: 18275907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective.
    Rester U
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):559-68. PubMed ID: 18600572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective.
    Zhao H
    Drug Discov Today; 2007 Feb; 12(3-4):149-55. PubMed ID: 17275735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian versus Frequentist statistical modeling: a debate for hit selection from HTS campaigns.
    Cloutier LM; Sirois S
    Drug Discov Today; 2008 Jun; 13(11-12):536-42. PubMed ID: 18549981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hit discovery and hit-to-lead approaches.
    Keseru GM; Makara GM
    Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Looking forward in pharmaceutical process chemistry.
    Davies IW; Welch CJ
    Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".
    Snowden M; Green DV
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):553-8. PubMed ID: 18600571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timely synthetic support for medicinal chemists.
    Potoski J
    Drug Discov Today; 2005 Jan; 10(2):115-20. PubMed ID: 15718160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image-based chemical screening.
    Carpenter AE
    Nat Chem Biol; 2007 Aug; 3(8):461-5. PubMed ID: 17637778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing discovery efficiency with a computationally driven fragment approach.
    Moore WR
    Curr Opin Drug Discov Devel; 2005 May; 8(3):355-64. PubMed ID: 15892251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The graphical representation of ADME-related molecule properties for medicinal chemists.
    Ritchie TJ; Ertl P; Lewis R
    Drug Discov Today; 2011 Jan; 16(1-2):65-72. PubMed ID: 21074634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basic overview of chemoinformatics.
    Engel T
    J Chem Inf Model; 2006; 46(6):2267-77. PubMed ID: 17125169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemogenomics: drug discovery's panacea?
    Jacoby E
    Mol Biosyst; 2006 May; 2(5):218-20. PubMed ID: 16880939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of virtual and high-throughput screening.
    Bajorath J
    Nat Rev Drug Discov; 2002 Nov; 1(11):882-94. PubMed ID: 12415248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From targets to leads: the importance of advanced data analysis for decision support in drug discovery.
    Fischer HP; Heyse S
    Curr Opin Drug Discov Devel; 2005 May; 8(3):334-46. PubMed ID: 15892249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational chemistry-driven decision making in lead generation.
    Schnecke V; Boström J
    Drug Discov Today; 2006 Jan; 11(1-2):43-50. PubMed ID: 16478690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Handing over the baton: connecting medicinal chemistry with process R&D.
    Federsel HJ
    Drug News Perspect; 2008 May; 21(4):193-9. PubMed ID: 18560618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.